Related by context. All words. (Click for frequent words.) 87 CYPHER ® Stent 73 CYPHER Stent 70 Taxus Stent 70 TAXUS 70 TAXUS stent 67 TAXUS Stent 67 paclitaxel eluting stents 66 TAXUS Liberte Stent 64 TAXUS Express Stent 64 sirolimus eluting stent 64 CYPHER R Sirolimus eluting 64 carotid stenting 64 Endeavor stent 64 SYNTAX trial 63 paclitaxel eluting stent 63 Cypher Stent 63 MACCE 63 SPIRIT IV 63 mm Stent 62 XIENCE V stent 62 Coronary Stent 62 drug eluting stents 62 TAXUS Express 62 TAXUS Liberte Long 62 SYNTAX 62 TAXUS Element Stent 62 carotid artery stenting 61 everolimus eluting stent 61 XIENCE V PROMUS Stent 61 XIENCE V 61 nonrandomized 61 Endeavor drug eluting 61 target lesion revascularization 61 CYPHER ® Sirolimus eluting 61 stenting 61 drug eluting stent 61 everolimus eluting stents 61 ischemic cardiomyopathy 61 RE LY ® 60 Resolute DES 60 TAXUS VI 60 TAXUS Liberte stent 60 definite stent thrombosis 60 GORE VIABAHN Endoprosthesis 60 active comparator 60 NEVO ™ 60 SPIRIT III 60 XIENCE V demonstrated 60 sirolimus eluting stents 60 endarterectomy 60 revascularization 60 TAXUS Liberte 60 TAXUS V 60 pegylated interferon alfa 2b 60 HORIZONS AMI trial 60 TAXUS R 60 prospective multicenter 60 MitraClip device 60 TRITON TIMI 59 carotid endarterectomy 59 zotarolimus eluting stent 59 stable angina 59 multivessel disease 59 binary restenosis 59 dual antiplatelet therapy 59 EVEREST II 59 rivaroxaban 59 thromboprophylaxis 59 FFR guided treatment 59 MitraClip 59 coronary interventions 59 patients undergoing percutaneous 59 dabigatran etexilate 59 acute coronary syndrome 59 repeat revascularization 59 TAXUS IV 59 PROMUS Element Stent 59 TAVI 58 Genous stent 58 Median survival 58 ENDEAVOR clinical 58 enoxaparin 58 telmisartan 58 ACTEMRA 58 vertebral fractures 58 NSTE ACS 58 Resolute drug eluting 58 randomized controlled clinical 58 STEMI patients 58 carotid endarterectomy CEA 58 TAXUS ® 58 placebo controlled clinical 58 bivalirudin 58 randomized Phase III 58 Dr. Kandzari 58 CABG surgeries 58 ticagrelor 58 ARIXTRA 58 patients undergoing CABG 58 coronary lesions 58 stent DES 58 acute coronary syndromes ACS 58 nondiabetic patients 57 CYPHER ® 57 SUPERA stent 57 TAXUS stents 57 de novo lesions 57 PRECiSE 57 prospective randomized 57 transcatheter aortic valve implantation 57 pCR 57 TAXUS TM 57 Stent System 57 severe aortic stenosis 57 MADIT CRT 57 Doxil ® 57 angiographic outcomes 57 stent thrombosis 57 coronary intervention 57 RE LY 57 percutaneous intervention 57 carotid artery stenting CAS 57 RESOLUTE clinical 57 revascularization procedures 57 multicenter randomized 57 ARCOXIA 57 ABSORB 57 placebo dexamethasone 57 NATRECOR ® 57 FOLFOX4 57 drug eluting stent DES 57 EchoCRT 57 TAXUS ATLAS 57 ONTARGET 57 composite endpoint 57 NEVO 57 FOLPI 56 prospective randomized controlled 56 aldosterone antagonist 56 tiotropium 56 reintervention 56 percutaneous coronary interventions 56 XIENCE V Everolimus Eluting 56 Events MACE 56 ADHF 56 transfemoral 56 Thrombolysis 56 valsartan 56 recurrent GBM 56 oncologic outcomes 56 chlorambucil 56 Stenting Trial CREST 56 statin therapy 56 stent implantation 56 clopidogrel 56 rosuvastatin 56 Atom Stent 56 TAXUS Liberté stent 56 TORISEL 56 LVEF 56 sirolimus eluting 56 Angiox R 56 unfractionated heparin 56 randomized clinical 56 Kaplan Meier analysis 56 decitabine 56 ipsilateral stroke 56 nonobstructive CAD 56 TAVR 56 bifurcation lesions 56 thrombolysis 56 diameter stenosis 56 SPIRIT FIRST 56 placebo controlled Phase III 56 radical nephrectomy 56 ACUITY trial 56 workhorse lesions 56 subtrochanteric 56 COPAXONE R 56 myocardial infarction MI 56 sunitinib malate 56 ATACAND 56 free survival PFS 56 DAPT 55 ExTRACT TIMI 55 multicenter prospective 55 coronary revascularization 55 acute coronary syndromes 55 KRAS mutations occur 55 PCIs 55 dosage regimens 55 paroxysmal AF 55 acute STEMI 55 symptomatic VTE 55 Coronary Stent System 55 stented 55 fondaparinux 55 Protelos 55 chemotherapy gemcitabine 55 sunitinib 55 reinfarction 55 defibrillator CRT D 55 MADIT CRT trial 55 FOLFOX 55 chemoradiotherapy 55 target vessel revascularization 55 azacitidine 55 NATRECOR R 55 median PFS 55 Endeavor DES 55 stent grafts 55 oral FTY# 55 Sirolimus eluting Coronary Stent 55 OPCAB 55 endovascular repair 55 Heparin Bioactive Surface 55 label multicenter 55 clopidogrel Plavix 55 carotid artery stenosis 55 candesartan 55 tirofiban 55 XGEVA 55 ACTEMRA TM 55 noninferiority 55 antiplatelet therapy 55 carotid surgery 55 thrombolytic therapy 55 tocilizumab 55 everolimus 55 ALLHAT 55 venous thromboembolism 55 Edwards SAPIEN valve 55 thrombus aspiration 55 ABSORB trial 55 primary patency 55 evaluating REVLIMID 55 stenoses 55 acute myocardial infarction AMI 55 perioperative mortality 55 acute ischemic stroke 55 randomized controlled clinical trials 55 reperfusion therapy 55 MitraClip R 55 tolvaptan 55 unstable angina UA 55 Betaferon ® 55 Zilver PTX 55 ENDEAVOR IV 55 levosimendan 55 vertebral fracture 55 Long Lesion 55 Tryton Side Branch 54 STELARA 54 CABG surgery 54 Express2 TM Paclitaxel Eluting 54 infarction STEMI 54 preoperative chemotherapy 54 randomized clinical trials 54 standard chemotherapy regimen 54 liver transplant recipients 54 multicentre randomized 54 vandetanib 54 systemic embolism 54 subgroup analyzes 54 nesiritide 54 balloon kyphoplasty 54 Stenting 54 intracranial stenosis 54 colorectal liver metastases 54 CYPHER 54 morphometric vertebral fractures 54 chemoradiation 54 interferon beta therapy 54 TAXUS Liberté 54 preintervention 54 atherothrombotic disease 54 TEVAR 54 peginterferon alfa 2a 54 adalimumab 54 lipid lowering therapy 54 EverFlex 54 TAXUS Express Atom Stent 54 PFO closure 54 tolerability 54 PERSEUS 54 pegylated liposomal doxorubicin 54 thromboembolic events 54 virologic failure 54 CABG 54 restenosis 54 eptifibatide 54 ximelagatran 54 Nitinol Stent 54 events MACE 54 oral diclofenac 54 CARE HF 54 plus dexamethasone 54 cilostazol 54 irbesartan 54 MADIT II 54 atherothrombosis 54 sirolimus stent 54 pioglitazone 54 adult chronic ITP 54 coronary stenting 54 #mg BID [001] 54 bronchial thermoplasty 54 carboplatin paclitaxel 54 octreotide LAR 54 BRIM2 54 recurrent stroke 54 Endeavor Resolute 54 nonfatal MI 54 antithrombotic therapy 54 eplerenone 54 eculizumab 54 imipenem 54 transapical 54 CUSTOM III 54 CIMZIA TM certolizumab pegol 54 rFVIIa 54 HORIZONS AMI 54 apixaban 54 stent BMS 54 ONGLYZA 54 SCD HeFT 54 posaconazole 54 randomized trials 54 revascularization procedure 54 undergoing coronary artery 53 lopinavir r arm 53 Myocardial Infarction Study 53 coronary artery disease 53 Major Adverse Cardiac 53 asymptomatic carotid stenosis 53 nonvertebral fracture 53 antiplatelet agents 53 non valvular atrial 53 Operative mortality 53 neoadjuvant therapy 53 EURIDIS 53 bisphosphonate therapy 53 PSADT 53 CYPHER R 53 CIMZIA ™ 53 Dabigatran 53 mycophenolate mofetil 53 primary percutaneous coronary 53 ST elevation myocardial 53 elective PCI 53 myocardial infarction 53 cryptogenic stroke 53 tipranavir r 53 ACCORD Lipid 53 CANCIDAS 53 GP IIb IIIa inhibitor 53 stent restenosis 53 functional mitral regurgitation 53 CYPHER R stent 53 FOSRENOL R 53 VADT 53 neoadjuvant 53 afatinib 53 antihypertensive therapy 53 Telmisartan 53 anti arrhythmic drug 53 Endarterectomy 53 NEVO TM 53 angioplasty stenting 53 comparator arm 53 neoadjuvant treatment 53 IFN alfa 53 paclitaxel eluting 53 multicenter 53 Tavocept 53 CYPHER R Sirolimus Eluting 53 oral anticoagulant 53 TACE 53 angiotensin receptor blocker ARB 53 PROMUS ® 53 symptomatic aortic stenosis 53 cinacalcet 53 hemodialysis patients 53 rosuvastatin #mg 53 uncoated stents 53 LMWH 53 macrovascular disease 53 Xience V 53 randomized controlled 53 tapentadol ER 53 colectomy 53 VIDAZA 53 VTE 53 multicenter clinical 53 randomized 53 carotid stenosis 53 angiographic 53 CIMZIA TM 53 Baseline characteristics 53 cytoreductive surgery 53 chronic angina 53 placebo controlled 53 Combo Stent 53 Vascular Wrap 53 mitral regurgitation 53 ZoMaxx 53 Acute Coronary Syndrome 53 conventional coronary angiography 53 tipranavir 53 Endeavor Resolute DES 53 placebo controlled trials 53 teriflunomide 53 PLCO 53 SYNERGY Stent 53 ROCKET AF 53 WallFlex Biliary RX 53 trastuzumab 53 Multicenter Automatic Defibrillator Implantation 53 stenting procedures 53 coronary artery bypass grafts 53 XIENCE PRIME 53 dronedarone 53 bevacizumab 53 postoperative mortality 53 Carotid Revascularization Endarterectomy vs. 53 vertebral compression fractures 53 TAXUS Express2 53 RTOG 52 VTE prophylaxis 52 plus prednisone 52 lipid lowering drugs 52 NYHA Class II 52 hsCRP levels 52 ICD implantation 52 GORE TAG Device 52 melphalan prednisone 52 NeuroStar TMS Therapy 52 sorafenib Nexavar 52 relapsing multiple sclerosis 52 axitinib 52 lymphadenectomy 52 peginterferon 52 multicentre 52 hepatectomy 52 mg kg dose 52 insulin glargine 52 mcg albinterferon alfa 2b 52 metastatic HRPC 52 sirolimus 52 acute PAO 52 left ventricular systolic 52 deep venous thrombosis 52 LEXIVA r 52 RESOLUTE 52 sustained virologic response 52 saphenous vein grafts 52 HbA1c levels 52 gemcitabine 52 AVOREN 52 biochemical recurrence 52 angioplasty procedures 52 VELCADE melphalan 52 trabectedin 52 stent thromboses 52 Cotavance 52 Val HeFT 52 Acute Coronary Syndromes 52 certolizumab 52 XELOX 52 ARB telmisartan 52 patency 52 Angiographic 52 thrombolytic agents 52 bypass grafts 52 mg QD 52 ACE inhibitor 52 DES implantation 52 parathyroidectomy 52 PressureWire 52 oral deforolimus 52 secondary endpoint 52 HSCT 52 dose cytarabine 52 cardiac resynchronization 52 heavily pretreated 52 TAXUS p value 52 Percutaneous Coronary Intervention 52 Eluting Coronary Stent System 52 HeFT 52 failure TVF 52 bioabsorbable stent 52 trials RCTs 52 riociguat 52 symptomatic carotid stenosis 52 hepatic resection 52 Fludara 52 pneumonectomy 52 bendamustine 52 conventional angiography 52 cardiovascular hospitalization 52 plus methotrexate 52 evaluable subjects 52 bypass graft CABG surgery 52 severe psoriasis 52 clinically localized prostate 52 strontium ranelate 52 GP IIb IIIa inhibitors 52 GAMMAGARD 52 lumbar spine BMD 52 phase IIIb 52 PROMUS Element Everolimus Eluting 52 doxorubicin docetaxel 52 abatacept 52 nab paclitaxel 52 low dose Iluvien 52 rt PA 52 carotid artery disease 52 AIM HIGH 52 unstable angina pectoris 52 nonoperative 52 MGuard 52 AngioSculpt 52 myocardial infarctions 52 warfarin therapy 52 revascularisation 52 baseline HbA1c 52 thromboembolic 52 myocardial infarction stroke 52 non inferiority 52 Acute Ischemic Stroke 52 Atacand 52 ivabradine 52 teriparatide 52 fluvastatin 52 aldosterone antagonists 52 Subgroup analyzes 52 PTNS 52 SEROQUEL 52 Zilver PTX stent 52 phase IIb clinical 52 infrapopliteal 52 PARTNER Trial 52 Free Survival PFS 52 carotid stent 52 CRESTOR #mg 52 oral allopurinol 52 reblockage 52 zoledronic acid 52 PROactive study 52 virologic response 52 Cordis Corporation 52 idraparinux 52 DCCT 52 microvascular complications 52 SLNB 52 RoACTEMRA 52 multicenter study 52 paclitaxel eluting coronary stent 51 CLARITY study 51 multicentre study 51 Hazard Ratio 51 dose dexamethasone 51 mg BID dose 51 evaluating tivozanib 51 Angiomax 51 endovascular procedures 51 recurrent VTE 51 incomplete revascularization 51 noninferior 51 oxycodone CR 51 dalteparin 51 dosing cohorts 51 CMV disease 51 Target Lesion Revascularization TLR 51 NYHA Class III 51 periprocedural 51 NSAID 51 recurrent glioblastoma multiforme 51 STRIDE PD 51 randomized multicenter 51 pain palliation 51 adjuvant tamoxifen 51 Mylotarg 51 ramipril 51 adjuvant radiotherapy 51 alteplase 51 transcatheter aortic valve 51 relapsed MM 51 DOXIL 51 chronic ITP patients 51 glimepiride 51 locoregional disease 51 imatinib 51 peginterferon alfa 2b 51 simvastatin ezetimibe 51 Sandostatin LAR 51 Edge STudy 51 dosing regimens 51 Drug Eluting Stents 51 ICD therapy 51 Bare Metal Stents 51 nephron sparing surgery 51 IV NSCLC 51 SYMBICORT 51 virologic 51 tamsulosin 51 ARIMIDEX 51 cerebrovascular events 51 hemodynamically significant 51 carotid revascularization 51 dacarbazine 51 coronary angiography 51 TMC# r 51 ICD implants 51 FFR guided 51 crizotinib PF # 51 pertuzumab 51 dose cohorts 51 DU #b 51 multicenter trials 51 Aromasin 51 balloon angioplasty 51 APTIVUS 51 IMPROVE HF 51 liver resection 51 CALGB # [002] 51 drug eluting coronary stents 51 postmenopausal osteoporotic women 51 percutaneous coronary intervention 51 metastatic RCC 51 aprotinin 51 intravenous bisphosphonates 51 APTIVUS r 51 aliskiren 51 patients evaluable 51 percutaneous transluminal coronary angioplasty 51 carotid artery stent 51 adjuvant therapy 51 TAXUS Liberté Stent 51 cisplatin chemotherapy 51 secondary efficacy endpoint 51 prospective multicenter study 51 anastrozole 51 TTF Therapy 51 randomized multicenter trial 51 Acute Myocardial Infarction 51 Drug eluting stent 51 statin 51 bioprostheses 51 microvascular disease 51 postintervention 51 NYHA class 51 placebo controlled Phase 51 PROMUS 51 iodixanol 51 Stent thrombosis 51 statins 51 landmark ATHENA 51 antithrombotics 51 relapsed refractory multiple myeloma 51 dose clopidogrel 51 concurrent chemoradiation 51 CCyR 51 ejection fractions 51 osteoporotic compression fractures 51 endovascular therapy 51 underwent CABG 51 NEVO RES 51 ascending dose 51 cardiac resynchronization therapy 51 prostatectomies 51 ablation procedures 51 double blinded randomized 51 EDSS scores 51 ischemic stroke 51 Phase III randomized 51 PRoFESS 51 endophthalmitis 51 methotrexate monotherapy 51 virological failure 51 risedronate 51 antiplatelet drugs 51 DMARD 51 evaluable 51 carotid stents 51 thromboses 51 advanced adenomas 51 HeartMate II 51 complete cytogenetic 51 HCV infected 51 relapsed AML 51 prasugrel Effient 51 oral anticoagulation 51 certolizumab pegol 51 vicriviroc 51 ACR# response 51 sitagliptin 51 stage IIIb IV 51 prospective multicenter randomized 51 analgesic efficacy 51 cardiovascular hospitalizations 51 Imprime PGG 51 Secondary endpoints 51 dose statin therapy 51 liposomal doxorubicin 51 DAS# scores 51 Taxotere ® 51 ezetimibe simvastatin 51 Randomized Evaluation 51 SORT OUT III 51 pazopanib 51 deep venous thromboses 51 esomeprazole 51 plus gemcitabine 51 Raptiva r 51 PNH patients 51 cardiac resynchronisation therapy 51 uncoated stent 51 Impella 51 dose regimens 51 FFR measurements 51 OZURDEX ® 51 Coronary artery bypass graft 51 sustained virological response 51 moxifloxacin 51 nonvertebral fractures 51 interventionalists 51 TG MV 51 infarct size 51 left ventricular dysfunction 51 HydroCoil 51 lacosamide 51 INTEGRILIN 51 tenecteplase 51 antiepileptic drug 51 graft patency 51 peginterferon alfa 2a #KD 51 splenectomized patients 51 mitral valve repair 51 PEGINTRON 51 chemoembolization 51 segment elevation myocardial 51 thoracoscopic lobectomy 51 BARI 2D 51 Perforomist Inhalation Solution 51 ALND 51 fibrinolytic therapy 50 blind randomized 50 INCB# [003] 50 SBRT 50 eluting stents 50 WBRT 50 atrial fibrillation AF 50 lamivudine monotherapy 50 plus MTX 50 coronary blockages 50 COR Analyzer 50 intermittent claudication 50 Bare Metal Stent 50 replacement TAVR 50 postoperative chemotherapy 50 EDSS score 50 subanalysis 50 phase III ACCLAIM 50 Sideguard 50 atorvastatin 50 LUX Lung 50 Vectibix monotherapy 50 unfractionated heparin UFH 50 EBRT 50 Cordis Cypher 50 arterial thromboembolic events 50 prostate TURP 50 anticoagulation therapy 50 venous thromboembolism VTE 50 β blockers 50 demonstrated clinically meaningful 50 chronic periodontitis 50 PASI scores 50 thoracic aortic 50 tamoxifen therapy 50 thrombotic events 50 GEM OS1 50 vinorelbine 50 neointimal hyperplasia 50 Amrubicin 50 hemoglobin A1c levels 50 cirrhotic patients 50 ™ Everolimus Eluting 50 pharmacodynamic profile 50 placebo controlled randomized 50 temsirolimus 50 gefitinib 50 pegylated interferon 50 APPRAISE 50 sipuleucel T 50 XIENCE 50 hypertensive patients 50 atherothrombotic events 50 stent 50 PRADAXA 50 blinded randomized 50 etanercept 50 #mg QD [002] 50 ImmuKnow assay 50 ACRIN 50 PROMUS Element 50 fully bioabsorbable 50 Drug Eluting Stent 50 candesartan cilexetil 50 Torisel 50 TAXUS Stents 50 LVAS 50 Acute Coronary Syndromes ACS 50 NHANES III 50 aspirin heparin 50 IVUS 50 Traficet EN 50 ENDEAVOR III 50 bosentan 50 multicenter randomized controlled 50 TAXUS paclitaxel eluting stent 50 transthoracic 50 LPV r 50 XIENCE TM 50 thromboembolic complications 50 SYNTAX Score 50 carotid IMT 50 evaluable patients 50 prospectively stratified 50 Everolimus Eluting Coronary Stent 50 Novacor LVAS 50 stent placement 50 cholecystectomy 50 lumiracoxib 50 ISENTRESS 50 Xience 50 VICTRELIS 50 rosiglitazone 50 thromboembolism 50 adjuvant chemotherapy 50 thoracic aortic aneurysms 50 PREZISTA r 50 receiving golimumab 50 Index CDAI score 50 EDEMA3 50 percutaneous aortic valve 50 UA NSTEMI 50 HBeAg positive patients 50 Angiox 50 infusional 5-FU/LV 50 TEMODAL 50 Screening Trial 50 dyslipidaemia 50 platinum chromium alloy 50 IIIa inhibitor 50 comorbidities 50 achieved PASI 50 resynchronization therapy 50 ReoPro 50 Engerix B 50 HBeAg seroconversion 50 underwent resection 50 Ceplene/IL-2 50 FOSRENOL ® 50 catheter angiography 50 relapsing remitting MS RRMS 50 Pivotal Trial 50 methotrexate therapy 50 TAXUS Element Paclitaxel Eluting 50 REALITY Trial 50 receiving VICTRELIS 50 controlled multicenter 50 letrozole 50 prospectively defined 50 mg BID 50 multicenter Phase III 50 osteoporotic fracture 50 ABC/3TC 50 PRIMO CABG 50 TAXUS Express2 Paclitaxel Eluting 50 multicenter placebo controlled 50 epoetin alfa 50 Taxotere R 50 BENICAR HCT 50 serum phosphorus 50 Sirolimus Eluting Coronary Stent 50 death reinfarction 50 oral rivaroxaban 50 Bivalirudin 50 cisplatin vinorelbine 50 platelet reactivity 50 BCIRG 50 HBeAg negative patients 50 percutaneous interventions 50 occluded artery 50 beta blocker therapy 50 ASCEND HF 50 pitavastatin 50 deferiprone 50 antihypertensive drugs 50 achieved ACR# 50 ZOSTAVAX 50 TYGACIL 50 DMARDs 50 graft occlusion 50 undergoing angioplasty 50 nephrectomy 50 Thal Dex 50 PEG INTRON 50 STEMI 50 HF ACTION 50 glufosfamide 50 clodronate 50 morbidity mortality 50 histologically confirmed 50 occlusive disease 50 SIR Spheres microspheres 50 iniparib 50 topotecan 50 platelet inhibitor 50 laboratory abnormalities 50 chemoradiation therapy 50 post thrombotic syndrome 50 superficial femoral 50 insulin detemir 50 substudy 50 radical cystectomy 50 AFib 50 discontinuations due 50 complete cytogenetic response 50 undergone radical prostatectomy 50 XIENCE V vs. 50 ReValving 50 dacarbazine chemotherapy 50 blind placebo controlled 49 nonfatal myocardial infarction 49 retinal thickness 49 aortic insufficiency 49 vertebroplasty 49 GnRH agonists 49 OLYMPIA registry 49 severe exacerbations 49 nonmetastatic prostate cancer 49 blinded randomized controlled 49 androgen deprivation 49 squamous histology 49 Clinical Outcomes Utilizing Revascularization 49 coronary artery stenosis 49 PROMUS TM 49 cardiac toxicity 49 gadobutrol 49 Catheter ablation 49 rimonabant #mg 49 aortic stenosis 49 TYKERB 49 amoxicillin clavulanate 49 RECORD1 49 primary hypercholesterolemia 49 REBETOL 49 losartan 49 aspirin therapy 49 onset atrial fibrillation 49 circulating EPCs 49 kidney transplant recipients 49 PREZISTA rtv 49 catheter occlusion 49 Taxus stent 49 pamidronate 49 ZOLINZA 49 cardiovascular mortality 49 CLL8 49 DAPT Study 49 daunorubicin 49 CR nPR 49 antihypertensive medications 49 PROMACTA 49 5-FU/LV 49 Express2 TM paclitaxel eluting 49 abciximab 49 colesevelam HCl 49 prospective randomized multicenter 49 UKPDS 49 oral antidiabetic medication 49 Novacor R 49 gemcitabine Gemzar 49 recurrent malignant glioma 49 Stent Thrombosis 49 forodesine 49 V Everolimus Eluting Coronary 49 pemetrexed 49 antiarrhythmic drug 49 LV dysfunction 49 VFEND 49 docetaxel chemotherapy 49 transcatheter 49 postoperative complications 49 rosuvastatin Crestor 49 mcg dose